GlassScriptPhysician profile
Mary Porter
NPI 1356489272
$3,217.19
in general payments reported to CMS, 2019-2025
28 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $78.88 · 2023: $791 · 2024: $912 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $532.25 | 2021-2025 | |
| Abbvie INC. | $519.44 | 2021-2025 | |
| Novo Nordisk INC | $288.19 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $263.78 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.52 | 2024-2025 | Caplyta |
| Amgen INC. | $138.92 | 2023-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $132.87 | 2025 | Veozah |
| Abbott Laboratories | $128.49 | 2024-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $117.97 | 2023-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.64 | 2022-2025 | Jardiance, Synjardy, Trijardy Xr |
| Axsome Therapeutics, INC. | $94.14 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $90.45 | 2023-2025 | Rexulti |
| Ardelyx, INC. | $76.31 | 2025 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $68.85 | 2023-2025 | Quviviq, Quviviq |
| Lilly USA, LLC | $64.32 | 2022-2024 | Zepbound, Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $63.28 | 2021-2022 | |
| Shield Therapeutics INC | $45.25 | 2023 | Accrufer |
| Medtronic, INC. | $42.96 | 2023-2025 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $42.44 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $38.90 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.68 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $36.69 | 2023-2024 | Cologuard Collection Kit |
| Tolmar, INC. | $20.98 | 2024 | |
| Tris Pharma INC | $20.87 | 2025 | Dyanavel Xr |
| Axonics, INC. | $18.66 | 2022 | |
| Inspire Medical Systems, INC. | $17.58 | 2024 | Inspire |
| Inari Medical, INC. | $16.39 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $15.37 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.